- (E) and (Z)-3-styrylpiperidines as sigma ligands
-
A class of (E) and Q-3-styrylpiperidine derivatives was prepared as racemates and evaluated for affinity at σ binding sites labeled with [3H]-(±-SKF-10,047. Some of these compounds exhibited high affinity and selectivity for σ verus D1 and D2 binding sites.
- Mantegani, Sergio,Brambilla, Enzo,Cremonesi, Paolo,Caccia, Carla,Fornaretto, Maria Gioia,Carfagna, Nicola,Colombo, Monica,McArthur, Robert A.,Varasi, Mario
-
-
Read Online
- NOVEL HISTONE METHYLTRANSFERASE INHIBITORS
-
The present invention relates to novel compounds of formula (I) as defined herein. The compounds are inhibitors of histone methyltransferases of the seven-beta-strand family, in particular of KMT9.
- -
-
-
- Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1 H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia
-
BCR-ABL kinase inhibition is an effective strategy for the treatment of chronic myeloid leukemia (CML). Herein, we report compound 3a-P1, bearing a difluoro-indene scaffold, as a novel potent pan-inhibitor against BCR-ABL mutants, including the most refractory T315I mutant. As the privileged (S)-isomer compared to its (R)-isomer 3a-P2, 3a-P1 exhibited potent antiproliferative activities against K562 and Ku812 CML cells and BCR-ABL and BCR-ABLT315I BaF3 cells, with IC50 values of 0.4, 0.1, 2.1, and 4.7 nM, respectively. 3a-P1 displayed a good safety profile in a battery of assays, including single-dose toxicity, hERG K+, and genotoxicity. It also showed favorable mice pharmacokinetic properties with a good oral bioavailability (32%), a reasonable half-life (4.61 h), and a high exposure (1386 h·ng/mL). Importantly, 3a-P1 demonstrated a higher potency than ponatinib in a mice xenograft model of BaF3 harboring BCR-ABLT315I. Overall, the results indicate that 3a-P1 is a promising drug candidate for the treatment of CML to overcome the imatinib-resistant T315I BCR-ABL mutation.
- Zhang, Dongfeng,Li, Peng,Gao, Yongxin,Song, Yaoyao,Zhu, Yaqin,Su, Hong,Yang, Beibei,Li, Li,Li, Gang,Gong, Ningbo,Lu, Yang,Shao, Huanjie,Yu, Chunrong,Huang, Haihong
-
p. 7434 - 7452
(2021/06/25)
-
- Stereoselective Activity of 1-Propargyl-4-styrylpiperidine-like Analogues That Can Discriminate between Monoamine Oxidase Isoforms A and B
-
The resurgence of interest in monoamine oxidases (MAOs) has been fueled by recent correlations of this enzymatic activity with cardiovascular, neurological, and oncological disorders. This has promoted increased research into selective MAO-A and MAO-B inhibitors. Here, we shed light on how selective inhibition of MAO-A and MAO-B can be achieved by geometric isomers of cis-and trans-1-propargyl-4-styrylpiperidines. While the cis isomers are potent human MAO-A inhibitors, the trans analogues selectively target only the MAO-B isoform. The inhibition was studied by kinetic analysis, UV-vis spectrum measurements, and X-ray crystallography. The selective inhibition of the MAO-A and MAO-B isoforms was confirmed ex vivo in mouse brain homogenates, and additional in vivo studies in mice show the therapeutic potential of 1-propargyl-4-styrylpiperidines for central nervous system disorders. This study represents a unique case of stereoselective activity of cis/trans isomers that can discriminate between structurally related enzyme isoforms.
- Knez, Damijan,Colettis, Natalia,Iacovino, Luca G.,Sova, Matej,Pi?lar, Anja,Konc, Janez,Le?nik, Samo,Higgs, Josefina,Kamecki, Fabiola,Mangialavori, Irene,Dol?ak, Ana,?akelj, Simon,Trontelj, Jurij,Kos, Janko,Binda, Claudia,Marder, Mariel,Gobec, Stanislav
-
p. 1361 - 1387
(2020/03/10)
-
- A kind of protease inhibitor and its preparation and use
-
The invention discloses a kind of protease inhibitors, and preparation method and application thereof. The invention discloses a kind of compounds and pharmaceutical compositions thereof, and a preparation method and application thereof. The invention relates to a kind of compounds capable of reducing or inhibiting activity of dual leucine zipper kinase in cells or a subject, and application of the compounds, or solvates, hydrates or medicinal salts thereof to prevent or treat patient diseases or related diseases caused by abnormity of dual leucine zipper kinase.
- -
-
Paragraph 0027-0029
(2018/03/25)
-
- A kind of to reduce the intraocular pressure of the compound and its preparation and use
-
The invention discloses a kind of compounds reducing intraocular pressure, and a preparation method and application thereof. The application is application to prepare medicines for reducing intraocular pressure. The above compounds have extremely substantial effect on reducing intraocular pressure.
- -
-
Paragraph 0028-0030
(2018/03/25)
-
- BTK INHIBITOR
-
Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV).
- -
-
Paragraph 0560-0561
(2017/11/16)
-
- PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS
-
Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa)
- -
-
-
- Protein Kinase Inhibitors
-
The present invention relates to compounds of Formula I: as well as pharmaceutically acceptable salts, hydrates, isomers, or solvates thereof, wherein the variables are described herein. The present invention further relates to pharmaceutical compositions which comprise the compounds of Formula I, and to methods for inhibiting protein kinase and methods of treating diseases, such as cancers, inflammation.
- -
-
Paragraph 0421; 0422
(2014/02/16)
-
- Hit-to-lead optimization of disubstituted oxadiazoles and tetrazoles as mGluR5 NAMs
-
Here we report the discovery and early SAR of a series of mGluR5 negative allosteric modulators (NAMs). Starting from a moderately active HTS hit we synthesized 3,5-disubstituted-oxadiazoles and tetrazoles as mGluR5 NAMs. Based on the analysis of ligand e
- Wágner, Gábor,Wéber, Csaba,Nyéki, Olga,Nógrádi, Katalin,Bielik, Attila,Molnár, László,Bobok, Amrita,Horváth, Attila,Kiss, Béla,Kolok, Sándor,Nagy, József,Kurkó, Dalma,Gál, Krisztina,Greiner, István,Szombathelyi, Zsolt,Keser, Gy?rgy M.,Domány, Gy?rgy
-
scheme or table
p. 3737 - 3741
(2010/08/20)
-
- Synthesis and evaluation of PSSRI-based inhibitors of Staphylococcus aureus multidrug efflux pumps
-
Phenylpiperidine selective serotonin reuptake inhibitors (PSSRIs) block the function of selected multidrug efflux pumps of Staphylococcus aureus. In this study PSSRI-based piperidine derivatives were prepared, evaluated for inhibition of two multidrug res
- German, Nadezhda,Kaatz, Glenn W.,Kerns, Robert J.
-
p. 1368 - 1373
(2008/12/23)
-
- FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS
-
A series of 5,6-dihydro-1-benzothiophen-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
- -
-
Page/Page column 58
(2008/06/13)
-
- TETRAZOLE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
-
The present invention relates to new compounds of formula (I) wherein Y1 and Y2 selected from the group consisting of hydrogen, halogen atom, C1-4 alkyl, C1-4 alkoxy or cyano group, X is oxygen or two hydrogen a
- -
-
Page/Page column 29
(2008/06/13)
-
- QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS
-
The present invention relates to substituted quinoline derivatives of Formula (I); wherein hal, n, A, formula (a) , R1, R2, R3, R4, R5 and R6 are defined herein, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-2 and/or neurokinin-3 (NK-3) receptors. These compounds can thus be used in methods of treatment to suppress and treat such disorders.
- -
-
Page/Page column 20-21
(2008/06/13)
-
- NOVEL PYRROLO [3, 2-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY
-
There are disclosed novel compounds of formula (I) wherein R1, R12, L, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing
- -
-
Page/Page column 40
(2010/11/08)
-
- NITROGENOUS HETEROCYCLIC DERIVATIVE HAVING 2,6-DISUBSTITUTED STYRYL
-
The invention provides a novel nitrogen-containing heterocyclic derivative having 2,6-disubstituted styryl and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the nitrogen-containing heterocyclic derivative and a pharmaceutically acceptable salt thereof, in particular, a pharmaceutical composition effective as a sodium channel inhibitor, having an excellent analgesic action especially on neuropathic pain with minimized side effects.
- -
-
Page/Page column 48
(2010/02/14)
-
- Chemokine receptor binding heterocyclic compounds with enhanced efficacy
-
The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
- -
-
-
- Synthesis and structure-activity relationships of novel IKK-β inhibitors. Part 2: Improvement of in vitro activity
-
A series of 2-amino-3-cyano-4-alkyl-6-(2-hydroxyphenyl)pyridine derivatives was synthesized and evaluated as IκB kinase β (IKK-β) inhibitors. Substitution of an aminoalkyl group for the aromatic group at the 4-position on the core pyridine ring resulted i
- Murata, Toshiki,Shimada, Mitsuyuki,Kadono, Hiroshi,Sakakibara, Sachiko,Yoshino, Takashi,Masuda, Tsutomu,Shimazaki, Makoto,Shintani, Takuya,Fuchikami, Kinji,Bacon, Kevin B.,Ziegelbauer, Karl B.,Lowinger, Timothy B.
-
p. 4013 - 4017
(2007/10/03)
-
- Sulfone derivatives as 5-HT7 receptor ligands
-
The present invention relates to sulfone derivatives of formula (I): Ar—SO2—CR2R3-L-N(R1)2??I wherein Ar, L, R1, R2 and R3 are as defined herein, and pharmaceutically
- -
-
Page/Page column 11
(2010/02/09)
-
- Pyridine derivatives
-
Pyridine compounds of general formula: wherein —R1represents in which R11is hydrogen, C1-6alkyl, halogen, hydroxy, C1-12alkoxy, nitro, amino, C1-6alkylsulfonylamino, C1-6alkoxycarbonyl, C1-6alkylamino, di(C1-6alkyl)amino, C1-6alkanoylamino, phenyl C1-6alkylamino, phenylsulfonylamino, or —O—(CH2)n—R111; R2represents hydrogen or halogen; R3represents hydrogen, —CR31R32R33, or —NR34R35; R4is hydrogen, carbamoyl, CN, carboxyl, etc.; R5is amino, C1-6alkylamino, di C1-6alkylamino, etc. or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.
- -
-
-
- Heterocyclic analgesic compounds and methods of use thereof
-
One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.
- -
-
-
- Heterocyclic analgesic compounds and methods of use thereof
-
One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.
- -
-
-
- Chemokine receptor binding heterocyclic compounds with enhanced efficacy
-
The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
- -
-
Page/Page column 11-12
(2010/02/03)
-
- Antipsychotic sulfonamide-heterocycles, and methods of use thereof
-
One aspect of the present invention relates to heterocyclic compounds comprising a sulfonamide moiety. A second aspect of the present invention relates to the use of the heterocyclic compounds comprising a sulfonamide moiety to treat diseases, afflictions or maladies caused at least in part by abnormal activity of one or more GPCRs or ligand-gated ion channels. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds comprising a sulfonamide moiety, and the screening of those libraries for biological activity, e.g., in animal models of psychosis.
- -
-
-
- CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationships.
-
CCR3 antagonist leads with IC(50) values in the microM range were converted into low nM binding compounds that displayed in vitro inhibition of human eosinophil chemotaxis induced by human eotaxin. In particular, 4-benzylpiperidin-1-yl-n-propylureas and erythro-3-(4-benzyl-2-(alpha-hydroxyalkyl)piperidin-1-yl)-n-propylureas (obtained via Beak reaction of N-BOC-4-benzylpiperidine) exhibited single digit nanomolar IC(50) values for CCR3.
- Wacker, Dean A,Santella 3rd., Joseph B,Gardner, Daniel S,Varnes, Jeffrey G,Estrella, Melissa,DeLucca, George V,Ko, Soo S,Tanabe, Keiichi,Watson, Paul S,Welch, Patricia K,Covington, Maryanne,Stowell, Nicole C,Wadman, Eric A,Davies, Paul,Solomon, Kimberly A,Newton, Robert C,Trainor, George L,Friedman, Steven M,Decicco, Carl P,Duncia, John V
-
p. 1785 - 1789
(2007/10/03)
-
- Heterocyclic analgesic compounds and methods of use thereof
-
One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.
- -
-
-
- Heterocycyclic piperidines as modulators of chemokine receptor activity
-
The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
- -
-
-
- Saturated heterocyclic carboxamide derivatives
-
A saturated heterocyclic carboxamide derivative of the following general formula (I) and salts thereof which have platelet activating factor (PAF) antagonizing activity. STR1
- -
-
-